Company Celebrates Significant Clinical Milestone WINNERSH, England, May 15 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS) today announced that Simon Sturge, Chief Executive Officer, will preside over the ringing of the NASDAQ closing bell on Thursday, May 18th at 4:00 p.m. (ET). Vernalis, whose ADR shares began trading on NASDAQ in July 1992, is celebrating the positive outcome of the Company's second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for the short-term (six-days per month) prevention of migraine in patients with migraines related to their menstrual cycles. The data from this study corroborate the positive findings in a prior efficacy study published in Neurology in July 2004 (ref: 2004, 63: 261-269). Vernalis is a specialty bio-pharmaceutical and drug development company with two marketed products and a broad development pipeline focused on neurology and central nervous system disorders. Vernalis' US partner, Endo Pharmaceuticals Inc., expects to file a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) in the coming weeks to seek approval for the additional indication of Frova(R) for the prevention of menstrual migraine. Frova(R) is currently FDA-approved for the acute treatment of migraine attacks with or without aura in adults where a clear diagnosis of migraine has been established. About the NASDAQ Closing Bell The NASDAQ Stock Market rings the closing bell at 4 p.m. and the ceremony will be available for viewing through NASDAQ's web cam: http://www.nasdaq.com/reference/marketsite_about.stm to watch the ceremony, beginning at 3:50 p.m. Viewers can scroll to the bottom of the page to access the MarketSite Live Web cam link. Windows Media Player is necessary to view the web cam. Local television stations may pick up the feed of the ceremony. The closing bell is available from 3:50 to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova(R) and Apokyn(R), and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec and Serono. Vernalis has established a US commercial operation to promote Apokyn(R) and co-promote Frova(R) alongside its North American licensing partner, Endo Pharmaceuticals, propelling the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit http://www.vernalis.com/. Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive Officer Tony Weir, Chief Financial Officer Julia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959 Jon Coles Wendel Verbeek Lazar Partners Ltd Gregory Gin 212-867-1762 Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products and including that of Frova(R) for menstrual migraine, the Company's ability to find partners for the development and commercialisation of its products, the benefits of re-acquiring Frova(R) in North America and the partnership with Endo on the Company's liquidity and results of operations, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, including with respect to Frova(R) and the Company's other products, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of Frova(R) and other products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova(R) and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. DATASOURCE: Vernalis plc CONTACT: Simon Sturge, Chief Executive Officer, Tony Weir, Chief Financial Officer, or Julia Wilson, Head of Corporate Communications, all of Vernalis plc, +44 (0) 118 977 3133; Jon Coles, or Wendel Verbeek, both of Brunswick Group, +44 (0) 20 7404 5959; Gregory Gin, Lazar Partners Ltd, +1-212-867-1762 Web site: http://www.vernalis.com/

Copyright